ArticleBreast cancer research and treatment2019
Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands.
Article in Breast cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Subtype-specific screen-detected and interval breast cancer rates in population screening: a BreastScreen Queensland cohort study.Breast (Edinburgh, Scotland) · 2026Article
- Vascular and mesenchymal signatures of breast cancers associated with Yo and Ri paraneoplastic syndrome.Breast cancer research : BCR · 2026Article
- Article
- Breast Cancer Specificities of Patients With Anti-Ri Paraneoplastic Neurologic Syndromes.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer.Breast cancer research : BCR · 2024Article
- High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients.Breast cancer research : BCR · 2023Article
- The impact of standardized structured reporting of pathology reports for breast cancer care.Breast (Edinburgh, Scotland) · 2022Article
- Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- Article
- Senescence Marker Protein 30 (SMP30): A Novel Pan-Species Diagnostic Marker for the Histopathological Diagnosis of Breast Cancer in Humans and Animals.International journal of molecular sciences · 2021Article
- Why is appropriate healthcare inaccessible for many European breast cancer patients? - The EBCC 12 manifesto.Breast (Edinburgh, Scotland) · 2021Article
- From Proteomics to Personalized Medicine: The Importance of Isoflavone Dose and Estrogen Receptor Status in Breast Cancer Cells.Journal of personalized medicine · 2020Article
- Changing patterns and survival improvements of young breast cancer in China and SEER database, 1999Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2019Article
- Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands.BMJ (Clinical research ed.) · 2019Article
- The influence of diabetes mellitus on blood vessels' amounts and immune status in case of breast cancer.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePatient management of invasive breast cancer (IBC) is to a large extent based on hormone- and HER2-receptor assessment. High-quality, reliable receptor assessment is of key importance as false results may lead to under- or overtreatment of patients. Surveillance of case-mix adjusted positivity rates has been suggested as a tool to identify laboratories with insufficient testing assays, as this covers the whole process of receptor assessment and enables laboratories to benchmark their positivity rates against other laboratories. We studied laboratory-specific variation in hormone- and HER2 positivity rates of 33,046 breast cancer patients using real-life nationwide data.
methodsAll synoptic pathology reports of IBC resection-specimens, obtained between 2013 and 2016, were retrieved from the nationwide Dutch pathology registry (PALGA). Absolute and case-mix adjusted receptor positivity rates were compared to the mean national proportion and presented in funnel plots in separate analyses for estrogen (ER), progesterone (PR) and HER2. Case-mix adjustment was performed by multivariable logistic regression.
results33,794 IBC lesions from 33,046 patients of 39 pathology laboratories were included. After case-mix adjustment, mean positivity rates were 87.2% for ER (range 80.4-94.3), 71.3% for PR (62.5-77.5%), and 9.9% for HER2 (5.5-12.7%). Overall, 14 (35.9%), 17 (43.6%) and 11 (28.2%) laboratories showed positivity rates outside the 95% confidence interval for ER, PR and HER2, respectively.
conclusionThis nationwide study shows that absolute variation in hormone- and HER2-receptor positivity rates between Dutch pathology laboratories is limited. Yet, the considerable number of outlying laboratories shows that there is still need for improvement. Continuous monitoring and benchmarking of positivity rates may help to realize this.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.